Application of bacteriophages
Expert Round Table Participants N , Rustam Aminov A , Jonathan Caplin B , Nina Chanishvili C , Aidan Coffey D , Ian Cooper E , Daniel De Vos F , Jiří Doškař G , Ville-Petri Friman H , İpek Kurtbӧke I , Roman Pantucek J , Jean-Paul Pirnay F , Grégory Resch K , Christine Rohde L , Wilbert Sybesma M and Johannes Wittmann LA School of Medicine and Dentistry, University of Aberdeen, UK
B School of Environment and Technology, University of Brighton, UK
C Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia
D Cork Institute of Technology, Department of Biological Sciences, Ireland
E School of Pharmacy and Biomolecular Sciences, University of Brighton, UK
F Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium
G Masaryk University, Faculty of Science, Department of Experimental Biology, Brno, Czech Republic
H University of York, Department of Biology, UK
I University of the Sunshine Coast, GeneCology Research Centre and the Faculty of Science, Health, Education and Engineering, Qld, Australia
J Masaryk University, Faculty of Science, Department of Experimental Biology, Brno, Czech Republic
K University of Lausanne, Department of Fundamental Microbiology, Switzerland
L Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
M Nestec Ltd – Nestlé Research Center, Lausanne, Switzerland
N Email: Phage_therapy@pha.ge
Microbiology Australia 38(2) 63-66 https://doi.org/10.1071/MA17029
Published: 11 April 2017
Abstract
The emergence of antibiotic-resistant bacteria and decrease in the discovery rate of novel antibiotics takes mankind back to the ‘pre-antibiotic era' and search for alternative treatments. Bacteriophages have been one of promising alternative agents which can be utilised for medicinal and biological control purposes in agriculture and related fields. The idea to treat bacterial infections with phages came out of the pioneering work of Félix d‘Hérelle but this was overshadowed by the success of antibiotics. Recent renewed interest in phage therapy is dictated by its advantages most importantly by their specificity against the bacterial targets. This prevents complications such as antibiotic-induced dysbiosis and secondary infections. This article is compiled by the participants of the Expert Round Table conference ‘Bacteriophages as tools for therapy, prophylaxis and diagnostics' (19–21 October 2015) at the Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia. The first paper from the Round Table was published in the Biotechnology Journal1. This
References
[1] Expert Round Table on Acceptance and Re-implementation of Bacteriophage Therapy (2016) Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnology J. 11, 595–600.[2] Aminov, R.I. (2010) A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol. 1, 134.
| A brief history of the antibiotic era: lessons learned and challenges for the future.Crossref | GoogleScholarGoogle Scholar |
[3] EMA (2015) Antimicrobial resistance. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000439.jsp
[4] CDC Report (2013) Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
[5] Zhang, Q.G. and Buckling, A. (2012) Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 5, 575–582.
| Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVGqsrjJ&md5=60d8cfadc6f2b4e90451e0d33574338cCAS |
[6] Yosef, I. et al. (2015) Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA 112, 7267–7272.
| Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXosVKruro%3D&md5=58e760fc2a470e40a117026c516f67cbCAS |
[7] Chanishvili, N. and Sharp, R. (2008) Bacteriophage therapy: experience from the Eliava Institute, Georgia. Microbiol. Aust. 29, 96–101.
[8] Servick, K. (2016) DRUG DEVELOPMENT. Beleaguered phage therapy trial presses on. Science 352, 1506.
| DRUG DEVELOPMENT. Beleaguered phage therapy trial presses on.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC28XhtV2rtrfJ&md5=0ab197dfa5b70392641e96e05977e67cCAS |
[9] Oechslin, F. et al. (2016) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J. Infect. Dis. , jiw632.
| Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence.Crossref | GoogleScholarGoogle Scholar |
[10] Bertozzi Silva, J. et al. (2016) Host receptors for bacteriophage adsorption. FEMS Microbiol. Lett. 363, fnw002.
| Host receptors for bacteriophage adsorption.Crossref | GoogleScholarGoogle Scholar |
[11] León, M. and Bastias, R. (2015) Virulence reduction in bacteriophage resistant bacteria. Front. Microbiol. 6, 343.
| Virulence reduction in bacteriophage resistant bacteria.Crossref | GoogleScholarGoogle Scholar |
[12] García, P.B. et al. (2008) Bacteriophages and their application in food safety. Lett. Appl. Microbiol. 47, 479–485.
| Bacteriophages and their application in food safety.Crossref | GoogleScholarGoogle Scholar |
[13] Endersen, L. et al. (2014) Phage therapy in food industry. Annu. Rev. Food Sci. Technol. 5, 327–349.
| Phage therapy in food industry.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXpt1Slsbo%3D&md5=4f0f609b666a92ed53b21c213a3d4c26CAS |
[14] Goodridge, L.D. and Abedon, S.T. (2008) Bacteriophage biocontrol: the technology matures. Microbiol. Aust. 29, 48–49.
[15] Monk, A.B. et al. (2010) Bacteriophage applications: where are we now? Lett. Appl. Microbiol. 51, 363–369.
| Bacteriophage applications: where are we now?Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3cfisVersA%3D%3D&md5=1d3aa42b44dd3bf0540b7a299e40a3aaCAS |
[16] Roy, B. et al. (1993) Biological inactivation of adhering Listeria monocytogenes by listeria bacteriophages and a quaternary ammonium compound. Appl. Environ. Microbiol. 59, 2914–2917.
| 1:CAS:528:DyaK3sXms1Kgsr8%3D&md5=ef13dab8ef5ac45d3d8c9a430fed02fdCAS |
[17] Wang, X. et al. (2017) Parasites and competitors suppress bacterial pathogen synergistically due to evolutionary trade‐offs. Evolution 71, 733–746.
| Parasites and competitors suppress bacterial pathogen synergistically due to evolutionary trade‐offs.Crossref | GoogleScholarGoogle Scholar |
[18] Addy, H.S. et al. (2012) Loss of virulence of the phytopathogen Ralstonia solanacearum through infection by φRSM filamentous bacteriophages. Phytopathology 102, 469–477.
| Loss of virulence of the phytopathogen Ralstonia solanacearum through infection by φRSM filamentous bacteriophages.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xos1Sktrc%3D&md5=59872ad8a60af1b498dc439d5b29848bCAS |
[19] Buttimer, C. et al. (2017) Bacteriophages and bacterial plant diseases. Front. Microbiol. 8, 34.
| Bacteriophages and bacterial plant diseases.Crossref | GoogleScholarGoogle Scholar |
[20] Patten, K. M. et al. (1995) Isolation of Dermatophilus congolensis phage from the ‘lumpy wool’ of sheep in Western Australia. Lett. Appl. Microbiol. 20, 199–203.
| Isolation of Dermatophilus congolensis phage from the ‘lumpy wool’ of sheep in Western Australia.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK2M3ksVSrsA%3D%3D&md5=616870f6033ec6e24ee88674785970e2CAS |
[21] Foulongne, V. et al. (2012) Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. PLoS One 7, e38499.
| Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XptlSnt7o%3D&md5=190d8cf92119a925ac60d7f8a5521aa0CAS |
[22] Mao, J. (2009) Genetically engineered phage fibers and coatings for antibacterial applications. MSc Thesis, Massachusetts Institute of Technology, USA.
[23] Fauconnier, A. (2017) Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines. EMBO Rep. 18, 198–200.
| Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2sXotlOmsA%3D%3D&md5=7d4ea35252aa4f041a8c9376e4c0d29dCAS |
[24] Kutter, E. et al. (2010) Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69–86.
| Phage therapy in clinical practice: treatment of human infections.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXkt1ems7k%3D&md5=4ffa5fddd9d9577ce3743fd202a5c742CAS |
[25] Commission de la santé publique, de l’environnement et du renouveau de la société (2016) Questions jointes de Mme Muriel Gerkens et M. Philippe Blanchart à la ministre des Affaires sociales et de la Santé publique sur ‘la phagothérapie’ à la ministre des Affaires sociales et de la Santé publique’ (N 11955 and N 12911). https://www.dekamer.be/doc/CCRA/pdf/54/ac464.pdf
[26] Murray, R.G.E. (1996) Taxonomic note: a rule about the deposition of type strains. Int. J. Syst. Bacteriol. 46, 831.
| Taxonomic note: a rule about the deposition of type strains.Crossref | GoogleScholarGoogle Scholar |
[27] Skurnik, M. and Strauch, E. (2006) Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5–14.
| Phage therapy: facts and fiction.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XjvV2ktro%3D&md5=dd1a6d58abe9b1003e143379c821f78bCAS |
[28] Pirnay, J.-P. et al. (2015) Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173–2179.
| Quality and safety requirements for sustainable phage therapy products.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXnvVSmtw%3D%3D&md5=205158929be1104c98e8591226e9d2c8CAS |
[29] Verbeken, G. et al. (2014) Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immunol. Ther. Exp. (Warsz.) 62, 117–129.
| Call for a dedicated European legal framework for bacteriophage therapy.Crossref | GoogleScholarGoogle Scholar |
[30] Fauconnier, A. (2017) Regulating phage therapy. Sci. Soc. 18, .
| Regulating phage therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2sXotlOmsA%3D%3D&md5=7d4ea35252aa4f041a8c9376e4c0d29dCAS |
